Who qualifies

Axiron and Androderm: Care and Claims

Used Axiron or Androderm and need a claim check? Keep the exact product, dates and care records.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202612 sources

This may apply to you if

  • Gather product names, prescriptions and dates you can confirm.
  • Keep diagnosis, treatment and authorized medical records.
  • Ask which proof, legal rules and personal time limit apply.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

U.S. Department of Health and Human Services · Publisher of the June 2026 FDA request announcement

Finding: FDA requested further revisions to age-related and prostate labeling information in June 2026. The announcement describes requested changes, not completed revisions to every product label.

HHS requested testosterone label updates (opens in a new tab) · Jun 18, 2026 · Checked Oct 4, 2026

The evidence and its limits

Cleveland Clinic and collaborating institutions; funded by AbbVie and others · New England Journal of Medicine · 2023

TRAVERSE cardiovascular safety trial

Design:
Randomized controlled trial
Participants:
5,246 men aged 45–80 with low testosterone symptoms and preexisting or high cardiovascular risk; randomized to daily 1.62% skin gel or placebo.
Finding:
Major cardiac events met the prespecified noninferiority criterion; atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
Main limitation
Specific male population and gel regimen; mean follow-up 33 months. Not zero-risk or lifetime safety evidence, and not proof of the cause of one person’s injury.

Read the source: TRAVERSE cardiovascular safety trial (opens in a new tab) · Checked Oct 4, 2026

U.S. Food and Drug Administration · 2025

FDA required blood-pressure monitoring study review

Design:
Agency review
Participants:
Review of required product-specific ambulatory blood-pressure studies; no single participant count supplied in the announcement.
Finding:
Completed studies showed increased blood pressure across testosterone products.
Main limitation
Agency summary of monitoring studies, not the TRAVERSE randomized enrollment or proof of one person’s injury cause.

Read the source: FDA required blood-pressure monitoring study review (opens in a new tab) · Checked Oct 4, 2026

The short answer

Who may have an Axiron or Androderm claim to check?
Ask about the product you used, harm and law. Keep a solution and patch history separate. A drug record alone does not mean a firm takes your case. [11]
What does not qualify as proof of an injury claim?
A warning or product name does not decide your own cause. An old label is not the latest class-wide information. The study does not cover every route equally. [5]
What if I switched between products?
Keep each drug, form and date separate. Ask the pharmacist about unclear names. Do not use one product’s guide for all forms. [11]
What records help explain the products and injury?
Keep pharmacy records, product details and care reports. Add any old packaging or medicine guide you already have. Mark dates you cannot confirm. [9]

What rules a case out

Not covered by this case

  • A study or court grouping does not decide a person’s cause, fault or payment.
  • No single national filing deadline is supplied.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

The criteria attorneys check

  1. 01

    Gather product names, prescriptions and dates you can confirm.

  2. 02

    Keep diagnosis, treatment and authorized medical records.

  3. 03

    Ask which proof, legal rules and personal time limit apply.

Used Axiron or Androderm and need a claim check? Keep the exact product, dates and care records. The solution and patch are different. New label findings do not decide your own cause.

Who may have an Axiron or Androderm claim to check?

Ask about the product you used, harm and law. Keep a solution and patch history separate. A drug record alone does not mean a firm takes your case.

The historical FDA labels identify Axiron as a topical solution and Androderm as a skin patch. They are distinct records with their own instructions. A lawyer needs the product used at the relevant time, rather than treating a court grouping or company headline as proof of responsibility.

What does not qualify as proof of an injury claim?

A warning or product name does not decide your own cause. An old label is not the latest class-wide information. The study does not cover every route equally.

The 2023 trial used one skin gel in selected men. Its main heart outcome stayed within the trial’s set risk margin. Some other harms occurred more often. FDA changed warnings in 2025 and requested more changes in June 2026. Those findings differ from older labels and do not set damages.

What if I switched between products?

Keep each drug, form and date separate. Ask the pharmacist about unclear names. Do not use one product’s guide for all forms.

The old Axiron label expressly describes its dose and application site as not interchangeable with other topical treatments. The Androderm record concerns a patch. Those historical records help identify products; they do not establish today’s availability or replace your clinician’s current instructions.

What records help explain the products and injury?

Keep pharmacy records, product details and care reports. Add any old packaging or medicine guide you already have. Mark dates you cannot confirm.

Separate the prescription history from the hospital diagnosis and any later cause opinion. Covered health-record access has exceptions and allowed copy fees. Ask the provider how to request the actual files instead of reconstructing a brand or dose from a news story.

Is there a deadline for these claims?

Ask a lawyer which claim and filing rule apply. No shared national deadline is supplied. A historical FDA label date is not a personal filing decision.

The original federal transfer concerned coordinated pretrial work, not a new filing window for every user. General court guidance makes the claim and applicable law important. Bring prior legal papers and any release or agreement for review rather than assuming a product switch restarted the clock.

What happens when I ask for a product claim check?

Confirm the receiving firm and proposed next step. Read fees and expenses before agreeing. Keep care decisions with your clinician.

Ask which product records are necessary and what gaps can be explained without guessing. Written recovery-based terms should address deductions and costs if unsuccessful. No clinical trial result, old warning or online inquiry guarantees representation, a payment or a particular medical plan.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. FDA February 2025 testosterone labeling changesFDA February 2025 testosterone labeling changes · regulator
  2. FDA current Testosterone InformationFDA current Testosterone Information · regulator
  3. HHS requested testosterone label updatesHHS requested testosterone label updates · regulator
  4. FORTESTA prescribing information and Medication Guide, July 2025FORTESTA prescribing information and Medication Guide, July 2025 · regulator
  5. Lincoff and colleagues: Cardiovascular Safety of Testosterone-Replacement TherapyLincoff and colleagues: Cardiovascular Safety of Testosterone-Replacement Therapy · study
  6. JPML initial testosterone products transfer orderJPML initial testosterone products transfer order · court
  7. Testosterone Topical: MedlinePlus Drug InformationTestosterone Topical: MedlinePlus Drug Information · regulator
  8. ABA Model Rule 1.5 feesABA Model Rule 1.5 fees
  9. HHS your medical recordsHHS your medical records · regulator
  10. SDNY how long do I have to file?SDNY how long do I have to file? · court
  11. FDA: Axiron October2016 label
  12. FDA: Androderm October2016 labelFDA: Androderm October2016 label · regulator

Checked against 12 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026